Vesper Medical is a privately held medical device company developing minimally invasive peripheral vascular products focused on treating deep venous disease. Its core product is the Vesper Duo™ Venous Stent System, a purpose-built family of venous stents designed to address anatomical challenges in the iliac and femoral veins. The company plans to complete development of the Duo system, run a large pivotal clinical trial and submit a Pre‑Market Approval (PMA) application to the U.S. FDA, and pursue CE Mark certification. Vesper cites deep venous disease as an under-treated condition affecting some 25 million U.S. adults and positions its stent portfolio to address those clinical needs. Vesper is a spinout of Intact Vascular and is using recently raised capital to advance development and regulatory milestones. The company’s devices are not approved for sale or use in the United States. Vesper Medical is advancing a differentiated portfolio of venous stents, including the Vesper Duo Venous Stent System, designed for the anatomical challenges of iliac and femoral veins. The company plans to use newly raised capital to complete development and perform in vivo testing required to obtain approvals for clinical testing of the Vesper Duo stents. Vesper is a privately held spinout of Intact Vascular and develops minimally invasive peripheral vascular products for deep venous disease. The company highlights a large addressable need, citing more than 25 million U.S. adults affected by deep venous disease and limitations of traditional treatments. Its press release cautions that the device is not approved for sale or use in the United States.

Total raised

$48M

Funding rounds

2

Latest round

Equity

Latest activity

May 2019